Celgene, Jounce in $2.6-bn immuno-oncology deal

Post Date: 
20 July 2016

Celgene and Jounce Therapeutics have linked in a global strategic collaboration striving to develop and commercialise immuno-oncology treatments.

The move gives Celgene options to jointly develop and commercialise Jounce's lead product candidate, JTX-2011, and additional innovative immunotherapies targeting B cells, T regulatory cells and tumor-associated macrophages.

In return, Jounce stands to receive an upfront payment of $225 million, a $36 million equity investment, and up to an additional $2.3 billion in future milestone payments across all programmes included in the collaboration.

Read more here